Johnson and Johnson (J&J) announced on Tuesday that its sales in the third quarter of the year saw an annual rise of 1.9% to reach $23.8 billion, surpassing expectations. The company's net earnings rose by 21.6% compared to the same trimester in 2021 to come in at $4.46 billion. Meanwhile, its diluted earnings per share jumped by 22.6% year-on-year to hit $1.68 per share.
"Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline," Chief Executive Officer (CEO) Joaquin Duato commented.
Following the release of the report, J&J's shares advanced by 2.10% in premarket trading.
